Hiroki Sameshima

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2019, Gastric Cancer.

Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study

T. Yoshikawa, Yoon-Koo Kang, S. Oh, 2021, Gastric Cancer.